Compare Neurocrine Biosciences Inc (NBIX) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Prudential Financial Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Prudential Financial Inc trades at $113.09 (market cap $39.17B). The key difference: Prudential Financial Inc is far larger — about 2.7× Neurocrine Biosciences Inc's market cap, and Prudential Financial Inc pays a 4.93% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Prudential Financial Inc for 145 Days on average.
| NBIX | PRU | |
|---|---|---|
Market Cap | $14.36B | $39.17B |
Volume | 1,237,180 | 1,436,917 |
Sector | Health | Financials |
52-Week High | $185.50 | $125.13 |
52-Week Low | $123.10 | $92.00 |
Typical Hold Time | 23 Days | 145 Days |
Enterprise Value | $14.37B | $67.95B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Prudential Financial (PRU) trades at $113.53, up 1.04% with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 10.29 and P/S of 0.61, while maintaining solid profitability with 6.04% net margin and 12.46% ROE. Recent developments include strategic partnerships, the Alexforbes stake sale, and rebranding to Prudential Wealth Advisors, reflecting ongoing business transformation.
PRU presents a mixed outlook with strong fundamentals offset by technical weakness. The company's $3 billion capital rotation plan and focus on core businesses provide growth potential, but investor sentiment remains cautious with 67.57% hold ratings. Key risks include execution of strategic initiatives and interest rate sensitivity, while current valuation below consensus target offers potential upside for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
